A detailed history of New York State Common Retirement Fund transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 63,571 shares of RARE stock, worth $2.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,571
Previous 54,724 16.17%
Holding current value
$2.78 Million
Previous $2.25 Million 57.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$40.21 - $59.36 $355,737 - $525,157
8,847 Added 16.17%
63,571 $3.53 Million
Q2 2024

Jul 31, 2024

SELL
$37.42 - $51.61 $281,548 - $388,313
-7,524 Reduced 12.09%
54,724 $2.25 Million
Q1 2024

May 07, 2024

SELL
$43.02 - $53.69 $456,786 - $570,080
-10,618 Reduced 14.57%
62,248 $2.91 Million
Q4 2023

Feb 01, 2024

BUY
$31.73 - $49.19 $624,224 - $967,714
19,673 Added 36.98%
72,866 $3.48 Million
Q3 2023

Nov 07, 2023

SELL
$34.92 - $46.66 $392,954 - $525,064
-11,253 Reduced 17.46%
53,193 $1.9 Million
Q2 2023

Aug 07, 2023

BUY
$37.35 - $52.15 $79,069 - $110,401
2,117 Added 3.4%
64,446 $2.97 Million
Q1 2023

May 02, 2023

SELL
$36.99 - $48.71 $268,954 - $354,170
-7,271 Reduced 10.45%
62,329 $2.5 Million
Q4 2022

Jan 30, 2023

SELL
$33.72 - $46.33 $1.83 Million - $2.52 Million
-54,395 Reduced 43.87%
69,600 $3.23 Million
Q3 2022

Nov 08, 2022

SELL
$39.96 - $66.14 $2.02 Million - $3.35 Million
-50,635 Reduced 29.0%
123,995 $5.14 Million
Q2 2022

Aug 04, 2022

SELL
$45.8 - $85.4 $476,777 - $889,014
-10,410 Reduced 5.63%
174,630 $10.4 Million
Q1 2022

May 05, 2022

BUY
$62.2 - $84.4 $101,821 - $138,162
1,637 Added 0.89%
185,040 $13.4 Million
Q4 2021

Feb 02, 2022

SELL
$73.71 - $87.86 $592,849 - $706,657
-8,043 Reduced 4.2%
183,403 $15.4 Million
Q3 2021

Nov 02, 2021

BUY
$77.92 - $102.4 $291,498 - $383,078
3,741 Added 1.99%
191,446 $17.3 Million
Q2 2021

Aug 02, 2021

BUY
$92.19 - $115.71 $2.75 Million - $3.45 Million
29,799 Added 18.87%
187,705 $17.9 Million
Q1 2021

May 11, 2021

BUY
$106.9 - $167.73 $1.08 Million - $1.69 Million
10,100 Added 6.83%
157,906 $18 Million
Q4 2020

Feb 08, 2021

BUY
$84.4 - $177.39 $1.42 Million - $2.98 Million
16,812 Added 12.83%
147,806 $20.5 Million
Q3 2020

Nov 05, 2020

BUY
$72.98 - $90.0 $226,238 - $279,000
3,100 Added 2.42%
130,994 $10.8 Million
Q2 2020

Aug 07, 2020

BUY
$46.91 - $78.22 $3.68 Million - $6.14 Million
78,494 Added 158.89%
127,894 $10 Million
Q1 2020

May 06, 2020

BUY
$33.8 - $62.9 $10,140 - $18,870
300 Added 0.61%
49,400 $2.2 Million
Q4 2019

Feb 05, 2020

SELL
$36.08 - $45.83 $303,072 - $384,972
-8,400 Reduced 14.61%
49,100 $2.1 Million
Q3 2019

Nov 07, 2019

BUY
$42.5 - $63.11 $63,750 - $94,665
1,500 Added 2.68%
57,500 $2.46 Million
Q2 2019

Aug 09, 2019

BUY
$54.93 - $74.36 $170,283 - $230,516
3,100 Added 5.86%
56,000 $3.56 Million
Q1 2019

May 08, 2019

BUY
$39.87 - $69.36 $271,116 - $471,648
6,800 Added 14.75%
52,900 $3.67 Million
Q4 2018

Feb 08, 2019

SELL
$38.89 - $77.3 $291,675 - $579,750
-7,500 Reduced 13.99%
46,100 $2 Million
Q3 2018

Nov 07, 2018

BUY
$71.81 - $90.15 $93,353 - $117,195
1,300 Added 2.49%
53,600 $4.09 Million
Q2 2018

Aug 10, 2018

BUY
$48.54 - $85.31 $218,430 - $383,895
4,500 Added 9.41%
52,300 $4.02 Million
Q1 2018

May 10, 2018

BUY
$44.33 - $58.52 $203,918 - $269,192
4,600 Added 10.65%
47,800 $2.44 Million
Q4 2017

Feb 13, 2018

SELL
$43.54 - $57.32 $1.17 Million - $1.54 Million
-26,836 Reduced 38.32%
43,200 $2 Million
Q2 2017

Aug 11, 2017

BUY
N/A
70,036
70,036 $4.35 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.06B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.